Compare NUVL & ALSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | ALSN |
|---|---|---|
| Founded | 2017 | 1915 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.1B |
| IPO Year | 2021 | 2012 |
| Metric | NUVL | ALSN |
|---|---|---|
| Price | $100.82 | $117.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | ★ $135.00 | $103.71 |
| AVG Volume (30 Days) | 497.6K | ★ 820.5K |
| Earning Date | 02-27-2026 | 02-23-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.15 |
| Revenue | N/A | ★ $3,069,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.88 |
| P/E Ratio | ★ N/A | $14.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.54 | $76.01 |
| 52 Week High | $113.02 | $118.75 |
| Indicator | NUVL | ALSN |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 67.64 |
| Support Level | $98.65 | $115.05 |
| Resistance Level | $106.57 | $118.75 |
| Average True Range (ATR) | 4.46 | 2.35 |
| MACD | -0.29 | -0.10 |
| Stochastic Oscillator | 47.36 | 68.29 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.